1,4-diazabicyclo[3.2.2]nonane-4-carboxylates and carboxamide derivates, production and use thereof in therapeutics
    1.
    发明授权
    1,4-diazabicyclo[3.2.2]nonane-4-carboxylates and carboxamide derivates, production and use thereof in therapeutics 有权
    1,4-二氮杂双环[3.2.2]壬烷-4-羧酸酯和羧酰胺衍生物,其在治疗中的生产和应用

    公开(公告)号:US06987106B1

    公开(公告)日:2006-01-17

    申请号:US09937045

    申请日:2000-03-21

    CPC分类号: C07D471/08

    摘要: Compounds of general formula in which X represents an oxygen atom or a group of formula NZ in which Z represents a hydrogen atom or an alkyl group, n represents a number 0, 1 or 2, and R1, R2, R3, R4 and R5 each represent a hydrogen or halogen atom or a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, alkyl, alkoxy, phenoxy or phenyl group optionally substituted with a halogen atom or a trifluoromethyl, cyano, hydroxyl, alkyl or alkoxy group, or alternatively R2 and R3 together form a group of formula —OCH2O— or —CH2CH2CH2CH2—. Application in therapy.

    摘要翻译: 其中X表示氧原子或式NZ的基团的通式的化合物,其中Z表示氢原子或烷基,n表示数字0,1或2,R 1, R 2,R 3,R 4和R 5各自表示氢或卤素原子或三氟甲基, 三氟甲氧基,氰基,羟基,烷基,烷氧基,苯氧基或苯基,任选被卤素原子或三氟甲基,氰基,羟基,烷基或烷氧基取代,或者R 2和R 3 一起形成式-OCH 2 O或-CH 2 CH 2 CH 2 CH 2的基团 > CH 2 - 。 应用于治疗。

    5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands
    2.
    发明授权
    5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands 失效
    5-苯基-3-(8-氮杂双环[3.2.1]辛-3-基)-1,3,4-恶二唑-2(3H) - 酮衍生物作为5-ht4受体配体

    公开(公告)号:US06255319B1

    公开(公告)日:2001-07-03

    申请号:US09403003

    申请日:1999-10-15

    IPC分类号: A61K3146

    CPC分类号: C07D451/04

    摘要: Compound of general formula (I) in which R1 represents an alkyl or cycloalkylmethyl group, X1 represents a hydrogen or halogen atom or an alkoxy group, or alternatively OR1 and X1 together represent an —OCH2O—, —O(CH2)2—, —O(CH2)3—, —O(CH2)2O— or —(CH2)3O— group, X2 represents a hydrogen atom or an amino group, X3 represents a hydrogen or halogen atom, and R2 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted phenylalkyl group or a group —(CH2)nCO—Z in which n represents a number from 1 to 6 and Z represents a 1-piperidyl group. Therapeutic application.

    摘要翻译: 通式(I)的化合物,其中R 1表示烷基或环烷基甲基,X 1表示氢或卤素原子或烷氧基,或者OR 1和X 1一起表示-OCH 2 O-,-O(CH 2)2 - O(CH 2)3 - , - O(CH 2)2 O-或 - (CH 2)3 O-基,X 2表示氢原子或氨基,X 3表示氢或卤素原子,R 2表示氢原子, 取代的烷基,任选取代的苯基烷基或基团 - (CH 2)n CO-Z,其中n表示1至6的数,Z表示1-哌啶基。 治疗应用。

    2,3-dihydrofuro [3,2-.beta.]pyridin, preparation and application thereof
in therapy
    3.
    发明授权
    2,3-dihydrofuro [3,2-.beta.]pyridin, preparation and application thereof in therapy 失效
    2,3-二氢呋喃并[3,2-b]吡啶,其制备及其在治疗中的应用

    公开(公告)号:US6143761A

    公开(公告)日:2000-11-07

    申请号:US381098

    申请日:1999-09-15

    CPC分类号: C07D491/04

    摘要: Compounds corresponding to the general formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom, a (C.sub.1 -C.sub.6)alkyl group or a phenyl(C.sub.1 -C.sub.4)alkyl group, R.sub.2 represents a hydrogen atom or a (C.sub.1 -C.sub.6)alkyl group and R.sub.3, R.sub.4 and R.sub.5 each represent, independently of one another, a hydrogen or halogen atom or a trifluoromethyl, cyano, hydroxyl, (C.sub.1 -C.sub.6)alkyl or (C.sub.1 -C.sub.6)alkoxy group. Application in therapeutics.

    摘要翻译: PCT No.PCT / FR98 / 00531 Sec。 371日期1999年9月15日 102(e)1999年9月15日PCT提交1998年3月17日PCT公布。 出版物WO98 / 42713 日期:1998年10月1日对应于通式(I)的化合物,其中R1表示氢原子,(C1-C6)烷基或苯基(C1-C4)烷基,R2表示氢原子或(C1 -C 6)烷基,R 3,R 4和R 5各自独立地表示氢或卤素原子或三氟甲基,氰基,羟基,(C 1 -C 6)烷基或(C 1 -C 6)烷氧基。 在治疗中的应用。

    5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for
use as 5-Ht4 or H3 receptor ligands
    5.
    发明授权
    5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-Ht4 or H3 receptor ligands 失效
    5-苯基-3-(哌啶-4-基)-1,3,4-恶二唑-2(3H) - 酮衍生物,用作5-Ht4或H3受体配体

    公开(公告)号:US5929089A

    公开(公告)日:1999-07-27

    申请号:US68390

    申请日:1998-05-08

    CPC分类号: C07D413/04 C07D413/14

    摘要: Compounds corresponding to the general formula (I) ##STR1## in which R.sub.1 represents a (C.sub.1 -C.sub.4)alkyl or (C.sub.3 -C.sub.7)cycloalkylmethyl group, X.sub.1 represents a hydrogen or halogen atom or a (C.sub.1 -C.sub.4)alkoxy group or else OR.sub.1 and X.sub.1 together represent a group of formula -OCH.sub.2 O-, -O(CH.sub.2).sub.2 -, -O(CH.sub.2).sub.3 -, -O(CH.sub.2).sub.2 O- or -O(CH.sub.2).sub.3 O-, X.sub.2 represents a hydrogen atom or an amino group, X.sub.3 represents a hydrogen or halogen atom, and R.sub.2 represents either a hydrogen atom or an optionally substituted (C.sub.1 -C.sub.6) alkyl group or a phenyl (C.sub.1 -C.sub.4) alkyl group which is optionally substituted on the phenyl ring or a phenyl (C.sub.2 -C.sub.3) alkenyl group or a phenoxy (C.sub.2 -C.sub.4) alkyl group or a cyclo (C.sub.3 -C.sub.7) alkylmethyl group or a 2,3-dihydro-1H-inden-1-yl or 2,3-dihydro-1H-inden-2-yl group or a group of general formula -(CH.sub.2).sub.n CO-Z in which n represents a number from 1 to 6 and Z represents a piperidin-1-yl or 4-(dimethylamino)piperidin-1-yl group. Application in therapeutics.

    摘要翻译: PCT No.PCT / FR96 / 01730 Sec。 371日期1998年5月8日 102(e)日期1998年5月8日PCT 1996年11月5日PCT PCT。 公开号WO97 / 17345 日期:1997年5月15日对应于通式(I)的化合物,其中R1表示(C1-C4)烷基或(C3-C7)环烷基甲基,X1表示氢或卤素原子或(C1-C4)烷氧基或 其中OR 1和X 1一起表示式-OCH 2 O-,-O(CH 2)2 - , - O(CH 2)3 - , - O(CH 2)2 O-或-O(CH 2)3 O- - 的基团, 原子或氨基,X3表示氢或卤素原子,R2表示氢原子或任选取代的(C1-C6)烷基或在苯环上任意取代的苯基(C1-C4)烷基 或苯基(C 2 -C 3)烯基或苯氧基(C 2 -C 4)烷基或环(C 3 -C 7)烷基甲基或2,3-二氢-1H-茚-1-基或2,3-二氢-1H-茚-1-基, 二氢-1H-茚-2-基或通式 - (CH 2)n CO-Z的基团,其中n表示1至6的数,Z表示哌啶-1-基或4-(二甲基氨基)哌啶-1-基, 吡啶-1-基。 在治疗中的应用。